Boston Scientific Stock (BSX) on December 3, 2025: Insider Sales, EU Device Win and Strong 2026 Price Targets

December 3, 2025 – Market close snapshot and latest news for Boston Scientific Corporation (NYSE: BSX).

Boston Scientific Corporation stock remains a closely watched name in large‑cap medical technology as 2025 winds down. On December 3, 2025, the BSX share price is hovering just below the psychological $100 mark, while new headlines about insider selling, fresh European device approvals and updated analyst targets shape the near‑term story for the stock. ^[1]

Below is a detailed look at how Boston Scientific stock is trading today, the most important news items from December 2–3, and what Wall Street now expects for 2026 and beyond.

Where Boston Scientific Stock Stands on December 3, 2025

As of late trading on December 3, 2025, Boston Scientific Corporation (BSX) is trading around $98.6 per share, modestly lower on the day. ^[2]

Key trading and valuation metrics:

Latest price: about $98.57 per share
Day’s range: roughly $97.6 – $99.3 ^[3]
52‑week range: approximately $85.98 – $109.50 ^[4]
Market capitalization: about $146 billion ^[5]
1‑year performance: up roughly 8–9% over the past 12 months ^[6]
Beta: around 0.67, indicating lower volatility than the broader equity market ^[7]

A MarketWatch recap of trading on December 2 noted that BSX closed at $99.02, about 9.6% below its 52‑week high of $109.50 reached in September, and slightly underperformed peers like Abbott, Medtronic and Stryker on that session. ^[8]

In other words, Boston Scientific stock is consolidating below recent highs, but still sits comfortably above its 52‑week low and modestly ahead of where it traded a year ago.

Fresh December Headlines: Insider Selling and a New EU Device Approval

Insider sales: EVP Arthur Butcher and wider insider activity

One of the most talked‑about BSX headlines this week is insider selling:

Arthur C. Butcher, Executive Vice President and Group President of MedSurg & APAC, sold 17,313 shares of Boston Scientific on December 1, 2025, at a weighted average price of about $101.55, for proceeds of roughly $1.76 million. ^[9]
Following the transaction, Butcher still holds 23,600 shares directly and 13,354 shares indirectly via a 401(k) plan. ^[10]
Importantly, the sale was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted in August 2024, which is designed to reduce the risk of trading on non‑public information. ^[11]

A separate analysis of recent Form 4 filings estimated that Boston Scientific insiders collectively sold around US$2.4 million of stock over the last 12 months, prompting some commentary that insiders may be signaling caution at current valuations. ^[12]

However, it’s worth stressing that insiders sell for many reasons — including diversification, tax planning and automatic trading plans — so the activity doesn’t necessarily indicate deteriorating fundamentals. Still, in a stock that already trades at a premium multiple, insider selling tends to get investors’ attention.

Big product news: EU approval for Farapoint pulsed field ablation catheter

On the positive side, Boston Scientific has scored a significant European regulatory win that reinforces one of its most important growth platforms:

On December 2, 2025, Boston Scientific received CE mark approval in Europe for its Farapoint focal pulsed field ablation (PFA) catheter, the latest addition to its Farapulse PFA portfolio. ^[13]
The CE mark expands the Farapulse platform’s capabilities to include treatment of right atrial flutter and targeted ablation of the cavotricuspid isthmus region in the heart. ^[14]
PFA is a newer energy modality that uses electric fields rather than heat or freezing to ablate cardiac tissue. Boston Scientific’s Farapulse system has already become a major growth driver, generating more than $1 billion in U.S. sales in its first year on the market, and this summer’s FDA approval expanded its reach into patients with more persistent atrial fibrillation. ^[15]

The Farapoint catheter is designed to perform focal and linear ablations, allowing physicians to draw precise lesion lines when connected to mapping systems, complementing Boston Scientific’s earlier Farawave basket‑style catheters. ^[16]

For BSX shareholders, this matters because:

PFA is widely seen as a multi‑billion‑dollar global opportunity in electrophysiology.
Additional indications and tools (like Farapoint and the next‑generation Faraflex catheter slated for 2027) strengthen Boston Scientific’s competitive moat in a space where Medtronic, J&J and others are also investing heavily. ^[17]

Watchman left‑atrial appendage closure: Next‑gen pipeline and market expansion

Boston Scientific’s Watchman left‑atrial appendage (LAA) closure device — used to reduce stroke risk in atrial fibrillation patients by sealing off the LAA — is another cornerstone of the company’s growth story:

The Watchman FLX Pro, a third‑generation version of the device, received FDA approval in 2023. ^[18]
At an investor presentation highlighted by MedTech Dive, company leaders outlined plans for a next‑generation Watchman system, aiming for launch in the second half of 2027 or early 2028, with design improvements intended to adapt more flexibly to differing cardiac anatomies. ^[19]
Management estimates the current Watchman market at about $2 billion, expecting it to grow at roughly 20% annually, helped by label expansions and increased use in combination with ablation procedures. ^[20]
The ongoing Champion‑AF trial compares Watchman against long‑term anticoagulant therapy, with results expected in the first half of 2026 — a potential catalyst if outcomes support broader indications and reimbursement. ^[21]

Watchman growth is closely tied to the success of Farapulse: Boston Scientific notes that around a quarter of U.S. Watchman cases already involve concomitant ablation, and updated U.S. reimbursement codes now support combined procedures, which could further support revenue growth. ^[22]

Investor sentiment: Bulls still vocal

Recent commentary from a Canadian investor interview on Cantech Letter characterized Boston Scientific as a beneficiary of a shift in patient and hospital preferences, underscoring continued institutional enthusiasm for the name. ^[23]

Taken together, insider selling, a major EU PFA approval, and continuing bullish investor commentary make early December an eventful period for BSX shareholders.

Q3 2025 Earnings Recap: Beat and Raised Guidance

The market’s current view of Boston Scientific stock is still anchored in the strong third‑quarter 2025 results and guidance hike announced on October 22, 2025.

Top‑line and bottom‑line beats

According to the company’s official press release, for Q3 2025 Boston Scientific reported: ^[24]

Net sales of $5.065 billion, up 20.3% year over year on a reported basis and 15.3% on an organic basis, exceeding both internal guidance (17–19% reported, 12–14% organic) and Wall Street consensus of about $4.97 billion.
GAAP net income attributable to shareholders of $755 million, or $0.51 per share, versus $0.32 a year ago.
Adjusted EPS of $0.75, up from $0.63 in the prior‑year quarter and ahead of consensus estimates around $0.71.

A follow‑up analysis from Nasdaq highlighted that adjusted gross margin reached about 71%, up roughly 60 basis points year over year, while adjusted operating margin rose to around 28%, an improvement of roughly 80 basis points, driven by favorable product mix (notably electrophysiology and Watchman) and operating leverage, partially offset by tariffs. ^[25]

Segment and regional performance

The company’s detailed tables show broad‑based growth across both businesses and geographies: ^[26]

Cardiology revenue grew about 24% year over year.
Peripheral Interventions grew around 17%.
The broader Cardiovascular segment rose more than 20%.
U.S. sales climbed roughly 27%, underscoring strong domestic demand, while APAC and Latin America/Canada also delivered double‑digit growth.

This mix underscores Boston Scientific’s balanced growth profile, combining scale in the U.S. with rising penetration in Europe and emerging markets.

Upgraded 2025 outlook

On the back of this performance, Boston Scientific raised its full‑year 2025 guidance: ^[27]

Net sales growth for 2025 is now projected at around 20% reported (up from prior 18–19%) and about 15.5% organic (up from 14–15%).
The company expects 2025 GAAP EPS of $1.97–$2.01, and adjusted EPS of $3.02–$3.04.
For Q4 2025, net sales are guided to grow roughly 14.5–16.5% reported and 11–13% organic versus the prior year.

Using the midpoint of the 2025 adjusted EPS range (~$3.03) and today’s share price near $98.6, BSX trades at roughly 33× 2025 adjusted earnings guidance, underlining the premium multiple investors are willing to pay for its high‑growth medtech portfolio.

Strategic Growth Drivers Beyond 2025

While Q3 numbers validate near‑term execution, the bullish case for Boston Scientific stock is largely about multi‑year structural growth.

Pulsed field ablation (Farapulse/Farapoint/Faraflex)

PFA is quickly becoming one of the most important technologies in interventional electrophysiology, and Boston Scientific is positioning itself as a category leader:

Farapulse: Generated over $1 billion in U.S. sales in its first year, and recent FDA actions expanded its approved patient population by roughly doubling the treatable atrial fibrillation pool. ^[28]
Farapoint: The newly approved focal PFA catheter in Europe extends the platform into right atrial flutter and more targeted lesion creation, backed by clinical data showing very low recurrence rates for atrial flutter at one‑year follow‑up. ^[29]
Faraflex: A next‑generation PFA catheter that can expand into a spherical, ringed shape with integrated mapping. First‑in‑human procedures have already been completed, with launch targeted for 2027. ^[30]

The PFA franchise ties directly into the Watchman ecosystem, making Boston Scientific a one‑stop solution provider for many AFib patients and strengthening its competitive standing against Medtronic, Abbott and J&J.

Structural heart and Watchman ecosystem

As highlighted above, the Watchman platform benefits from:

An expanding addressable market (management sees the potential to grow from about 5 million patients currently served to over 20 million by 2030, pending trial data and label expansions). ^[31]
Growing use in concomitant procedures with ablation, supported by updated Medicare payment codes. ^[32]
A next‑generation device aiming for launch in 2027–2028, which should help Boston Scientific defend and expand its share in LAA closure. ^[33]

Broader portfolio and M&A

Boston Scientific also continues to rely on targeted acquisitions to fill portfolio gaps and enter adjacent markets:

Recently, an analysis from Zacks (though partially blocked by anti‑bot protections) emphasized that BSX’s M&A strategy has been a key contributor to growth, helping it expand in high‑growth markets and reinforce core franchises. ^[34]
The company has also been investing in areas like weight‑loss solutions (Endura Weight Loss Solutions) and leadless pacing and modular cardiac rhythm management (mCRM), with its EMPOWER leadless pacemaker system expected to pursue FDA approval in 2025. ^[35]

Altogether, BSX is positioned as a high‑growth, innovation‑driven medtech platform, rather than a slow‑growing device manufacturer.

What Wall Street Expects Now: Price Targets and Ratings

Analysts remain broadly constructive on Boston Scientific stock, and multiple data providers show meaningful upside over the next 12 months:

MarketBeat: 25 analysts have an average 12‑month price target of about $123.77, with a range of $108–$140, implying roughly 25–26% upside from a current price around $98.5. ^[36]
StockAnalysis.com: 19 covering analysts rate BSX a “Strong Buy”, with an average target of $124.53 (low $110, high $140), implying about 26% upside. ^[37]
BTIG/Nasdaq summary: As of mid‑November, the average one‑year price target compiled there was $128.25, with a range from $102.46 to $147.00, representing roughly 33% upside from a then‑current price near $96.60. ^[38]
StocksGuide: Aggregating 36 analyst estimates, the site reports an average target of about $129.54, with a high forecast of $147.00 and a low around $102.47, implying ~31% upside. ^[39]
Tikr blog: A recent analysis pegs the Street’s average price target at roughly $126 per share, with a high of $140, low of $99, median $130, and a skewed rating mix of 25 Buys, 7 Outperforms and only 2 Holds. ^[40]
DirectorsTalkInterviews: Another recent piece framed BSX as offering roughly 24.5% upside based on its own target calculations, supported by a cluster of “Strong Buy” ratings. ^[41]

Across these sources, the signal is consistent:

Wall Street’s consensus view is that Boston Scientific stock offers roughly 25–30% upside over the next year, with bull‑case targets in the $140–$147 range and very few outright bearish calls.

At the same time, these bullish targets rest on expectations that Boston Scientific can sustain mid‑teens organic revenue growth, expand margins and successfully execute on major pipeline drivers like PFA, Watchman label expansion and leadless pacing.

Valuation, Risks and the Bear Case

Even bulls generally concede that BSX is not a cheap stock:

StockAnalysis data show a trailing P/E near 53× and a forward P/E around 30×, already embedding a significant growth premium relative to the broader healthcare sector. ^[42]
On the company’s own 2025 adjusted EPS guidance (~$3.02–$3.04), today’s share price in the high‑$90s implies a low‑30s multiple of next year’s earnings.

Recent commentary from Yahoo Finance and Barchart has noted that, despite strong fundamentals, BSX shares have pulled back mid‑single digits over the last three months, even while the business continues to post robust returns and frequent new highs earlier in the year. ^[43]

Key risks that skeptics highlight include:

Valuation risk: At ~30× forward earnings, any slowdown in procedure volumes, pricing pressure or delayed reimbursement could lead to multiple compression.
Competition: A recent Baron Health Care Fund letter summarized Boston Scientific’s share‑price weakness partly as a function of intensifying competition in several device categories, including structural heart and electrophysiology. ^[44]
Regulatory and tariff exposure: The Q3 margin commentary explicitly cited tariffs as a headwind, partially offsetting mix benefits — an issue that could worsen if trade tensions escalate. ^[45]
Execution on pipeline: The Street’s bullish targets assume successful launches and label expansions (Faraflex, next‑gen Watchman, EMPOWER leadless pacemaker, etc.). Any negative trial results or regulatory delays could impair the long‑term growth story. ^[46]

Finally, insider selling — including Mr. Butcher’s recent sale and the broader ~$2.4 million of stock sold by insiders over the last year — may reinforce a narrative of cautious profit‑taking near highs, even though such sales can have benign motivations. ^[47]

What to Watch Next for BSX Investors

Looking ahead from December 3, 2025, key milestones and data points for Boston Scientific shareholders include:

Q4 2025 results and 2026 guidance
- Investors will closely track whether the company hits its Q4 guidance (mid‑teens revenue growth) and whether management signals another year of double‑digit organic growth in 2026. ^[48]
Champion‑AF trial data (Watchman vs. anticoagulants)
- Positive results in 2026 could unlock a much larger patient population and support the company’s aspiration to expand Watchman eligibility from roughly 5 million patients to over 20 million globally by 2030. ^[49]
Farapoint rollout and PFA adoption trends
- The uptake of Farapoint in Europe, along with any future U.S. approval, will be a key indicator of how entrenched Boston Scientific can become in the rapidly evolving PFA space. ^[50]
Tariffs and margin trajectory
- Investors will watch how tariffs and input costs evolve, and whether gross margin can hold around the low‑70% level despite pricing pressure and macro headwinds. ^[51]
Further M&A and portfolio moves
- Boston Scientific has a long track record of using M&A to accelerate growth; additional deals — especially in high‑growth adjacencies like obesity, neuromodulation or structural heart — could change the earnings trajectory again. ^[52]

For now, the base case on December 3, 2025 is that BSX remains a premium‑valued growth medtech leader, with strong fundamental momentum, a few fresh catalysts (EU Farapoint approval, Watchman next‑gen program, raised 2025 guidance) and a generally bullish analyst community — tempered by insider selling and a valuation that leaves less room for error.